Article
Chemistry, Multidisciplinary
Jianhua Xiong, Xiaoyu Wang, Jaewon Kim, Jiankang Gong, Zhiqiang Mao, Jong Seung Kim, Zhihong Liu
Summary: A ROS-triggered self-immolative therapeutic prodrug, through the combination of photodynamic therapy and chemical therapy, can kill most non-CSCs tumor cells and block the growth of CSCs, thus increasing the therapeutic index.
ADVANCED FUNCTIONAL MATERIALS
(2023)
Review
Medicine, General & Internal
Elisa Stellaria Grassi, Viola Ghiandai, Luca Persani
Summary: Recent studies have shown intratumoral heterogeneity in thyroid cancer, with cancer stem-like cells hypothesized to drive tumor heterogeneity, contributing to its metastatic potential and therapy resistance. These cancer stem cells primarily exist in specific tumor areas, known as stem cell niches.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Health Care Sciences & Services
Mariachiara Buccarelli, Giorgia Castellani, Lucia Ricci-Vitiani
Summary: Angiogenesis plays a crucial role in the growth and progression of GBM, and targeting GBM angiogenesis in cancer therapy has gained increasing attention. However, recent studies have shown that anti-angiogenic treatments have limited effects and can lead to tumor resistance and increased aggressiveness. This review summarizes the neovascularization processes associated with GBM and discusses the drug resistance mechanisms underlying the transient efficacy of current anti-angiogenic therapies. Potential strategies and perspectives to overcome GBM's resistance to anti-angiogenic therapy are also described as new potential therapeutic approaches.
JOURNAL OF PERSONALIZED MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Zhen-Ling Liu, Huan-Huan Chen, Li-Li Zheng, Li-Ping Sun, Lei Shi
Summary: Angiogenesis is a complex process regulated by various molecules and plays a crucial role in tumor growth and metastasis. Targeted therapeutic research based on these molecules has led to the emergence of promising anti-angiogenic strategies in cancer therapy.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Review
Chemistry, Multidisciplinary
Pingping Liang, Byron Ballou, Xinyi Lv, Weili Si, Marcel P. Bruchez, Wei Huang, Xiaochen Dong
Summary: Anti-angiogenic therapy targeting vascular endothelial cells to prevent tumor growth has shown modest clinical efficiency in solid tumors. Combining advanced drug delivery techniques or other therapeutic strategies with anti-angiogenic therapy can result in significantly synergistic effects in fighting cancer. Clinical difficulties of traditional anti-angiogenic therapy are discussed, while promising applications of anti-angiogenic nanoagents in monotherapies and combination therapies are highlighted.
ADVANCED MATERIALS
(2021)
Review
Biochemistry & Molecular Biology
Filipa Lopes-Coelho, Filipa Martins, Sofia A. Pereira, Jacinta Serpa
Summary: Anti-angiogenic therapy aims to fight cancer by disrupting the nutrient and oxygen supply to tumor cells, mainly by targeting vascular endothelial growth factor (VEGF). While some drugs in this category can enhance immune therapy, they often fall short in terms of efficacy. Researchers believe that targeting alternative angiogenic pathways in combination could be a promising solution.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Hejing Bao, Ling Zhen Ma, Chengzhu Zhao, Mengge Yu, Baishen Zhang, Juan Zhang, Guibao Peng, Xiaotong Lin, Yinhua Fang, Hehong Bao, Shudong Ma
Summary: This study examined the efficacy and safety of anti-angiogenic therapy combined with chemotherapy compared to traditional chemotherapy for advanced PPLELC patients. The results showed that patients who received anti-angiogenic therapy combined with chemotherapy had a longer progression-free survival (PFS) compared to those who received chemotherapy alone. Anti-angiogenic therapy combined with chemotherapy is recommended as an optional treatment for advanced PPLELC.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Valeria Nele, Valentina Tedeschi, Virginia Campani, Raffaella Ciancio, Alessia Angelillo, Sossio Fabio Graziano, Giuseppe De Rosa, Agnese Secondo
Summary: Neurodegenerative diseases are characterized by mitochondrial dysfunction and abnormal levels of reactive oxygen species (ROS). In this study, we developed cerium-based nanomaterials with ROS-scavenging properties and combined them with lipid self-assembling nanoparticles (SANP). These cerium-doped SANP (Ce-SANP) showed good colloidal properties and mimicked the activity of ROS-scavenging enzymes. Ce-SANP rescued neuronal cells from mitochondrial damage under ischemic conditions by reducing ROS production and preventing ATP level reduction. Furthermore, Ce-SANP restored mitochondrial Ca2+ handling and showed potential for the treatment of neurodegenerative diseases by managing ROS levels and mitochondrial function.
Article
Endocrinology & Metabolism
Su Jung Hwang, Yeonghun Jung, Ye-Seul Song, Suryeon Park, Yohan Park, Hyo-Jong Lee
Summary: A novel melatonin derivative, N-butyryl-5-methoxytryptamine (NB-5-MT), showed potent targeting activity against HIF-1 alpha, leading to decreased angiogenesis, reactive oxygen species generation, and tumor growth, with enhanced anti-angiogenic effects compared to melatonin. NB-5-MT represents a promising lead for the development of anticancer compounds targeting HIF-1 alpha, offering potential as a novel therapeutic agent for cancer with overexpressed HIF-1 alpha.
JOURNAL OF PINEAL RESEARCH
(2021)
Review
Oncology
Amirhossein Izadpanah, Niloufar Mohammadkhani, Mina Masoudnia, Mahsa Ghasemzad, Arefeh Saeedian, Hamid Mehdizadeh, Mansour Poorebrahim, Marzieh Ebrahimi
Summary: Accumulating data has shown that cancer stem cells (CSCs) play a crucial role in tumor metastasis and recurrence. Targeting CSC-related signaling pathways and surface markers could help eradicate tumors and improve cancer survival. Immunotherapy strategies, such as dendritic cell (DC) vaccines, chimeric antigen receptors (CAR)-engineered immune cells, and monoclonal antibodies (mAbs), have shown promising results in targeting CSCs.
Review
Pharmacology & Pharmacy
Bandana Chakravarti, Jawed Akhtar Siddiqui, Rohit Anthony Sinha, Sana Raza
Summary: Cancer stem cells (CSCs) are a subset of cancer cells that possess the ability to self-renew and initiate tumors. CSCs exhibit resistance to traditional therapies and are a major driver of disease relapse. Recent studies have revealed that CSCs have distinct metabolic properties, and metabolic reprogramming plays a crucial role in their self-renewal and maintenance.
BIOCHEMICAL PHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Cristobal Aguilar-Gallardo, Mauricio Zamorano, Jorge G. Farias, Karol De Aguiar Quevedo
Summary: Cancer stem cells (CSCs) play a crucial role in tumor development and metastasis. These cells possess self-renewal and differentiation abilities, similar to stem cells, but with malignant characteristics. The harsh tumor microenvironment induces autophagy in CSCs, enhancing their stemness and promoting tumorigenicity and metastasis. Understanding the relationship between hypoxia-induced autophagy and CSCs proliferation may lead to new cancer treatment strategies.
MOLECULAR BIOLOGY REPORTS
(2022)
Review
Chemistry, Multidisciplinary
Bicai Tang, Wenjuan Ma, Yunfeng Lin
Summary: Studies have shown the potential of nanomaterials in inhibiting pathological angiogenesis, providing new options for cancer treatment. Compared to traditional anti-angiogenic agents, nanomaterials have better targeting capabilities and therapeutic outcomes, reducing side effects.
JOURNAL OF CONTROLLED RELEASE
(2023)
Review
Oncology
Saket Jain, Eric J. Chalif, Manish K. Aghi
Summary: Glioblastoma, an aggressive brain tumor, has poor treatment outcomes due to low T-cell infiltration and dysfunction in the tumor microenvironment. Recent developments in single-cell sequencing and anti-angiogenic therapy offer new therapeutic opportunities. Inhibiting angiogenesis can increase immune cell infiltration and enhance the efficacy of immunotherapy. Combining anti-angiogenic therapy and immunotherapy shows promise in improving survival rates for glioblastoma patients.
FRONTIERS IN ONCOLOGY
(2022)
Article
Medicine, Research & Experimental
Ajit Venniyoor
Summary: The combination of anti-angiogenic agents with immune checkpoint inhibitors has shown promise in altering tumor microenvironment and enhancing treatment efficacy. In addition, anti-angiogenic therapy may increase tumor mutational burden, making tumors more vulnerable to immune checkpoint inhibitors.
MEDICAL HYPOTHESES
(2021)
Article
Oncology
Vanitha N. Sivalingam, Ayse Latif, Sarah Kitson, Rhona McVey, Katherine G. Finegan, Kay Marshall, Michael P. Lisanti, Federica Sotgia, Ian J. Stratford, Emma J. Crosbie
BRITISH JOURNAL OF CANCER
(2020)
Article
Cell Biology
Bela Ozsvari, Federica Sotgia, Michael P. Lisanti
Article
Cell Biology
Camillo Sargiacomo, Federica Sotgia, Michael P. Lisanti
Article
Cell Biology
Matteo Brindisi, Marco Fiorillo, Luca Frattaruolo, Federica Sotgia, Michael P. Lisanti, Anna Rita Cappello
Article
Cell Biology
Marco Fiorillo, Fanni Toth, Matteo Brindisi, Federica Sotgia, Michael P. Lisanti
Review
Biochemistry & Molecular Biology
Francesca De Santis, Giovanni Fuca, Dirk Schadendorf, Alberto Mantovani, Luca Magnani, Michael Lisanti, Stephen Pettitt, Matteo Bellone, Giannino Del Sal, Saverio Minucci, Alexander Eggermont, Paolo Bruzzi, Silvio Bicciato, Pierfranco Conte, Roberta Noberini, John Hiscott, Filippo De Braud, Michele Del Vecchio, Massimo Di Nicola
Summary: Experts at the Tenth Edition of the Annual Congress on Anticancer Innovative Therapy shared the latest knowledge and novel therapeutic approaches in fields such as immuno-oncology, epigenetics, cancer metabolism, cancer stem cells, tumor cell signaling, and the immune system. The conference also discussed possible mechanisms of resistance to these innovative therapies, particularly with respect to immune checkpoint blockers (ICB), providing a broad overview of future challenges and hopes for improving cancer treatment in the medium-short term.
CYTOKINE & GROWTH FACTOR REVIEWS
(2021)
Article
Multidisciplinary Sciences
Cristian Scatena, Giovanni Fanelli, Giuseppe Nicolo Fanelli, Michele Menicagli, Paolo Aretini, Valerio Ortenzi, Sara Piera Civitelli, Lorenzo Innocenti, Federica Sotgia, Michael P. Lisanti, Antonio Giuseppe Naccarato
Summary: Recent evidence indicates that loss of caveolin expression in the stromal compartment of human invasive breast carcinoma may be predictive of disease recurrence, metastasis, and poor prognosis. Additionally, a study on sCav-1 expression in breast cancer and axillary lymph nodes suggests that the loss of Cav-1 in lymph nodes may contribute to metastatic spread in breast cancer.
SCIENTIFIC REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Marco Fiorillo, Cristian Scatena, Antonio Giuseppe Naccarato, Federica Sotgia, Michael P. Lisanti
Summary: This study identifies high ATP production by the mitochondrial ATP-synthase as a new therapeutic target for anticancer therapy, particularly for inhibiting tumor progression. ATP-high cancer cells exhibit aggressive phenotypes with increased proliferation, stemness, anchorage-independence, cell migration, invasion, and multi-drug resistance, along with high antioxidant capacity. ATP depletion through targeting ATP5F1C may serve as a promising strategy for preventing metastasis and avoiding treatment failure, making ATP5F1C a potential biomarker and molecular target for future drug development to prevent metastatic disease progression.
CELL DEATH AND DIFFERENTIATION
(2021)
Article
Oncology
Camillo Sargiacomo, Sophie Stonehouse, Zahra Moftakhar, Federica Sotgia, Michael P. Lisanti
Summary: MTDR can be used to target and eradicate cancer stem cells by selectively interfering with mitochondrial metabolism in breast cancer cells. It significantly inhibits tumor growth and metastasis with little to no toxicity observed in a preclinical animal model.
FRONTIERS IN ONCOLOGY
(2021)
Article
Cell Biology
Filippo Di Pisa, Elisa Pesenti, Maria Bono, Andrea N. Mazzarello, Cinzia Bernardi, Michael P. Lisanti, Giovanni Renzone, Andrea Scaloni, Ermanno Ciccone, Franco Fais, Silvia Bruno, Paolo Scartezzini, Fabio Ghiotto
Summary: This study sheds light on the potential role of SH3BGRL3 in regulating myosin-cytoskeleton interaction and cell migration. It was found that SH3BGRL3 specifically interacts with Myo1c in a Ca2+-dependent manner, suggesting a potential regulatory mechanism for cytoskeleton dynamics involving SH3BGRL3 and Myo1c.
BMC MOLECULAR AND CELL BIOLOGY
(2021)
Review
Oncology
Marco Fiorillo, Bela Ozsvari, Federica Sotgia, Michael P. Lisanti
Summary: The study suggests that high mitochondrial ATP production is a new therapeutic target for cancer treatment, isolating metabolically fit cancer cells with enhanced stem-like properties and invasive abilities. By regulating mitochondrial ATP-synthase, prevention of metastasis in cancer cells is possible.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Matteo Brindisi, Luca Frattaruolo, Marco Fiorillo, Vincenza Dolce, Federica Sotgia, Michael P. Lisanti, Anna Rita Cappello
Summary: This study found that elevated cholesterol levels increase the aggressiveness of breast cancer cells and promote the release of pro-inflammatory factors. Furthermore, there is a close symbiotic relationship between breast cancer cells and the microenvironment. These findings highlight the potential of targeting the cholesterol-ERR alpha synergy for breast cancer treatment.